Literature DB >> 23060409

Exposures to 1,3-dimethylamylamine-containing products reported to Texas poison centers.

Mb Forrester1.   

Abstract

1,3-Dimethylamylamine (DMAA) is an ingredient in a number of weight loss and exercise performance enhancing products. However, information on the safety of DMAA-containing products is limited. Exposures to DMAA-containing products reported to Texas poison centers during 2010-2011 were identified and selected factors were examined. A total of 56 exposures were found, of which 75.0% were reported during 2011. OxyElite Pro™ was the reported product in 80.4% of the exposures. The patients were 51.8% male and 55.4% age ≤5 years. The patient was managed on site (such as at home) in 57.1% of the cases, and the exposure was known or expected to result in an outcome that was classified as not serious in 80.4%. The most frequently reported clinical effects were tachycardia (28.6%), nausea (16.1%), and vomiting (12.5%). The most common treatments were dilution (41.1%), food (19.6%), and activated charcoal (14.3%). It should be noted that the adverse clinical effects may be due to other ingredients in the DMAA-containing products, such as caffeine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23060409     DOI: 10.1177/0960327112454895

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  9 in total

1.  Abuse liability of the dietary supplement dimethylamylamine.

Authors:  Sean B Dolan; Michael B Gatch
Journal:  Drug Alcohol Depend       Date:  2014-11-25       Impact factor: 4.492

2.  Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.

Authors:  Charles M Skinner; Isabelle R Miousse; Laura E Ewing; Vijayalakshmi Sridharan; Maohua Cao; Haixia Lin; D Keith Williams; Bharathi Avula; Saqlain Haider; Amar G Chittiboyina; Ikhlas A Khan; Mahmoud A ElSohly; Marjan Boerma; Bill J Gurley; Igor Koturbash
Journal:  Food Chem Toxicol       Date:  2018-09-30       Impact factor: 6.023

Review 3.  Adverse Effects of Nutraceuticals and Dietary Supplements.

Authors:  Martin J J Ronis; Kim B Pedersen; James Watt
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

4.  A Retrospective Study of Clinical Effects of Powdered Caffeine Exposures Reported to Three US Poison Control Centers.

Authors:  Gillian A Beauchamp; Amberly R Johnson; Barbara I Crouch; Matthew Valento; B Zane Horowitz; Robert G Hendrickson
Journal:  J Med Toxicol       Date:  2016-04-04

5.  Effects of controlled doses of Oxyelite Pro on physical performance in rats.

Authors:  Paulo Vinicios Camuzi Zovico; Victor Magalhães Curty; Marcos André Soares Leal; Eduardo Frizzera Meira; Daniel Ventura Dias; Lívia Carla de Melo Rodrigues; Silvana Dos Santos Meyrelles; Edilamar Menezes De Oliveira; Paula Frizera Vassallo; Valério Garrone Barauna
Journal:  Nutr Metab (Lond)       Date:  2016-12-06       Impact factor: 4.169

6.  Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products.

Authors:  Manuela Pellegrinia; Maria Concetta Rotolo; Francesco Paolo Busardò; Roberta Pacifici; Simona Pichini
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Sympathomimetic amine compounds and hepatotoxicity: Not all are alike-Key distinctions noted in a short review.

Authors:  Cyril Willson
Journal:  Toxicol Rep       Date:  2018-12-01

Review 8.  Dietary Supplements as Source of Unintentional Doping.

Authors:  Vanya Rangelov Kozhuharov; Kalin Ivanov; Stanislava Ivanova
Journal:  Biomed Res Int       Date:  2022-04-22       Impact factor: 3.246

Review 9.  Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States.

Authors:  Mark I Avigan; Robert P Mozersky; Leonard B Seeff
Journal:  Int J Mol Sci       Date:  2016-03-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.